Citigroup Inc Hille Vax, Inc. Transaction History

Citigroup Inc

$190 Billion
Q1 2025

A detailed history of Citigroup Inc transactions in Hille Vax, Inc. stock. As of the latest transaction made, Citigroup Inc holds 24,042 shares of HLVX stock, worth $50,969. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,042

Previous 25,076 4.12%

Holding current value

$50,969

Previous $51,000 33.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$1.45 - $2.14 $1,499 - $2,212	-1,034 Reduced 4.12%	24,042 $34,000
Q4 2024 Feb 12, 2025	BUY	$1.72 - $2.06 $2,760 - $3,306	1,605 Added 6.84%	25,076 $51,000
Q3 2024 Nov 12, 2024	BUY	$1.58 - $14.42 $25,972 - $237,035	16,438 Added 233.73%	23,471 $41,000
Q2 2024 Aug 12, 2024	BUY	$11.86 - $15.93 $26,744 - $35,922	2,255 Added 47.2%	7,033 $101,000
Q1 2024 May 10, 2024	BUY	$14.15 - $19.75 $14,164 - $19,769	1,001 Added 26.5%	4,778 $79,000
Q4 2023 Feb 09, 2024	BUY	$10.35 - $17.11 $32,944 - $54,461	3,183 Added 535.86%	3,777 $60,000
Q3 2023 Nov 09, 2023	SELL	$11.59 - $16.7 $76,957 - $110,888	-6,640 Reduced 91.79%	594 $7,000
Q2 2023 Aug 10, 2023	BUY	$12.93 - $18.76 $85,441 - $123,966	6,608 Added 1055.59%	7,234 $124,000
Q1 2023 May 11, 2023	SELL	$14.73 - $18.18 $2,842 - $3,508	-193 Reduced 23.57%	626 $10,000
Q4 2022 Feb 09, 2023	BUY	$13.52 - $21.46 $8,395 - $13,326	621 Added 313.64%	819 $13,000
Q3 2022 Nov 10, 2022	SELL	$10.5 - $22.01 $6,268 - $13,139	-597 Reduced 75.09%	198 $3,000
Q2 2022 Aug 10, 2022	BUY	$8.7 - $20.18 $6,916 - $16,043	795 New	795 $9,000

Others Institutions Holding HLVX

# of Institutions

Shares Held

34.9M

Call Options Held

Put Options Held

View Full List

About HilleVax, Inc.

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $70.9M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

More about HLVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account